Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28417731 | 0.79 | FLT3 (0.49) | ADORA2AFLT3PRMT5WDR77JAK2 | |
| SCHEMBL25045604 | 0.79 | CYP1A2 (0.33) | — | |
| SCHEMBL27399219 | 0.79 | TGFBR1 (0.44) | FLT3TGFBR1 | |
| SCHEMBL31051302 | 0.79 | TGFBR1 (0.44) | FLT3TGFBR1 | |
| SCHEMBL30218126 | 0.76 | MAP3K14 (0.33) | TGFBR1 | |
| SCHEMBL3325146 | 0.76 | POLB (0.51) | FLT3PRMT5WDR77 | |
| SCHEMBL13336367 | 0.76 | CYP1A2 (0.53) | KDM4EALDH1A1HPGDCYP11B1CYP11B2 | |
| SCHEMBL1353156 | 0.76 | TGFBR1 (0.50) | ADORA2AFLT3KDM4EALDH1A1HPGD | |
| SCHEMBL24087021 | 0.76 | TGFBR1 (0.43) | ADORA2AFLT3KDM4ECYP11B1CYP11B2 | |
| SCHEMBL16460211 | 0.76 | ALDH1A1 (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2391625-B1 | New adenosine receptor ligands and uses thereof | DOMAIN THERAPEUTICS (FR) | 2013-05-01 | — | — | EP | disclosed |
| EP-2391625-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | Domain Therapeutics (FR) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| WO-2010084425-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-2210891-A1 | New adenosine receptor ligands and uses thereof | Domain Therapeutics (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885FLT3 1986/4885KDM4E 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.